Venture Certified
| 연구개발유형 | 2022-09-28 ~ 2025-09-27 | 20220928020022 | 2022-09-28 |
| 연구개발유형 | 2025-09-28 ~ 2028-09-27 | 20250827020017 | 2022-09-28 |
Revenue CAGR +48.6%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.4B | 0.2B | 0.2B |
| Operating Profit | -0.8B | -1.1B | -0.4B |
| Net Profit | -0.9B | -1.3B | -0.4B |
| Total Assets | 2.8B | 2.2B | 2.8B |
| Total Liabilities | 3.6B | 3.4B | 2.8B |
| Total Equity | -0.8B | -1.2B | 0.0B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -799210K
3 Consecutive Years of Net Loss
▲ 95.2%
▼ 4.5%
▲ 44.0%
▼ 110.2%
▲ 117.5%
| Name | Position | Role |
|---|---|---|
| 조문제 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "제주특별자치도 제주시",
"ceo_name": "조문제",
"certificate": [
{
"cert_number": "20220928020022",
"changes": "",
"disclosure_date": "2022-09-28",
"first_cert_date": "2022-09-28",
"no": "1",
"type": "연구개발유형",
"valid_period": "2022-09-28 ~ 2025-09-27"
},
{
"cert_number": "20250827020017",
"changes": "",
"disclosure_date": "2025-08-27",
"first_cert_date": "2022-09-28",
"no": "2",
"type": "연구개발유형",
"valid_period": "2025-09-28 ~ 2028-09-27"
}
],
"company_name": "주식회사 에이켐바이오",
"corp_no": "134111-*******",
"financials": {
"2022": {
"capital_stock": 182000000,
"cost_of_sales": 0,
"current_assets": 94358000,
"current_liabilities": 77362000,
"gross_profit": 16650000,
"net_income": -42712000,
"net_income_bs": -42712000,
"non_current_assets": 186151000,
"non_current_liabilities": 200000000,
"non_operating_expenses": 7336000,
"non_operating_income": 2967000,
"operating_profit": -38343000,
"revenue": 16650000,
"sga_expenses": 54993000,
"total_assets": 280509000,
"total_equity": 3147000,
"total_liabilities": 277362000
},
"2023": {
"capital_stock": 182000000,
"cost_of_sales": 0,
"current_assets": 49970000,
"current_liabilities": 129011000,
"gross_profit": 21000000,
"net_income": -125889000,
"net_income_bs": -125889000,
"non_current_assets": 169203000,
"non_current_liabilities": 212904000,
"non_operating_expenses": 12359000,
"non_operating_income": 1143000,
"operating_profit": -114673000,
"revenue": 21000000,
"sga_expenses": 135673000,
"total_assets": 219173000,
"total_equity": -122742000,
"total_liabilities": 341915000
},
"2024": {
"capital_stock": 313681000,
"cost_of_sales": 0,
"current_assets": 128899000,
"current_liabilities": 137226000,
"gross_profit": 36755000,
"net_income": -90221000,
"net_income_bs": -90221000,
"non_current_assets": 148772000,
"non_current_liabilities": 222774000,
"non_operating_expenses": 11923000,
"non_operating_income": 1622000,
"operating_profit": -79920000,
"revenue": 36755000,
"sga_expenses": 116675000,
"total_assets": 277671000,
"total_equity": -82329000,
"total_liabilities": 360000000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [],
"main_products": "신약 연구개발",
"phone": "064-756-****",
"years": [
2024,
2023,
2022
]
}